Drugs / rivogenlecleucel

Trials 10

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 15 trials
Phase 1 NCT03807063 Jan → Dec 2020 B-cell chronic lymphocytic leukemia, CD4+/CD56+ hematodermic neoplasm, acute biphenotypic leukemia, bilineal acute myeloid leukemia +4 Fred Hutchinson Cancer Center Withdrawn No outcome recorded Stop: Business
Phase 1 NCT02487459 Jul 2016 → Jun 2017 hematopoietic and lymphoid cell neoplasm Bellicum Pharmaceuticals Withdrawn No outcome recorded
Phase 1 NCT02477878 Jul 2016 → Jan 2020 overdue leukemia, myelodysplastic syndrome, plasma cell myeloma Bellicum Pharmaceuticals Active not recruiting No outcome recorded
Phase 1 NCT02786485 May 2016 → Dec 2018 leukemia, myelodysplastic syndrome, plasma cell myeloma Bellicum Pharmaceuticals Withdrawn No outcome recorded
Phase 1 NCT02231710 Feb → Sep 2015 bone marrow failure syndrome, hemoglobinopathy, hemophagocytic syndrome, immunodeficiency disease +1 Bellicum Pharmaceuticals Terminated No outcome recorded Stop: Enrollment
Phase 1/23 trials
Phase 1/2 NCT03733249 Jan 2017 → Jun 2020 Diamond-Blackfan anemia, Fanconi anemia, acute lymphoblastic leukemia, childhood acute myeloid leukemia +5 Bellicum Pharmaceuticals Terminated No outcome recorded
Phase 1/2 NCT02065869 Apr 2014 → Jun 2020 Diamond-Blackfan anemia, Fanconi anemia, acute lymphoblastic leukemia, childhood acute myeloid leukemia +5 Bellicum Pharmaceuticals Terminated No outcome recorded Stop: Business
Phase 1/2 NCT01744223 Mar 2013 → Oct 2019 overdue acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome Bellicum Pharmaceuticals Active not recruiting No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT03699475 Dec 2018 → Jul 2019 acute myeloid leukemia, myelodysplastic syndrome Bellicum Pharmaceuticals Terminated No outcome recorded Stop: Business
Phase not stated1 trial
— NCT03639844 — Hurler syndrome, metachromatic leukodystrophy Bellicum Pharmaceuticals No longer available No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as Rivogenlecleucel “Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients...” NCT02065869 ↗
5

NCT03639844 ↗

NCT03733249 ↗

NCT03699475 ↗

NCT03807063 ↗

NCT02786485 ↗

Known as BPX 501 “a BPX 501 infusion (T cells genetically modified with the inducible Caspase 9 suicide gene)” NCT02231710 ↗
5

NCT01744223 ↗

NCT02477878 ↗

NCT02231710 ↗

NCT02487459 ↗

NCT02065869 ↗

Modality Cell therapy “2x10E5 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501)” NCT01744223 ↗
Route Other “BPX-501 infused after partially mismatched, related (haploidentical), T cell-depleted HSCT” NCT01744223 ↗